Notable Labs, Ltd.
DelistedCIK 1603207fmd_0PX1CR1382F2S8B9BNFNDEWT81Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2015 to Jun 30, 2024, 28 periods
| Line item | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | 1 | 1 | 1 | 1 | – | 0 |
| Cost of revenue | – | – | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net interest income | – | – | – | – | – | – | 0 | (0) | – |
| Gross profit | – | – | 14 | 0 | 0 | 1 | 0 | 0 | 0 |
| Research and development | (11) | (12) | 18 | 15 | 15 | 20 | 23 | 8 | 5 |
| Selling, general and administrative | (4) | (4) | 6 | 5 | 5 | – | – | – | – |
| Total operating expenses | – | – | – | – | – | – | – | 13 | 15 |
| Operating income | 15 | 16 | 10 | 21 | (20) | (24) | (30) | (13) | (15) |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | – |
| Interest and investment income | – | – | – | – | 1 | 0 | 0 | 1 | – |
| Other non-operating income (expense) | – | – | – | (1) | 1 | 0 | 0 | (1) | 3 |
| Net income | – | – | – | 20 | (19) | (24) | (30) | (14) | (11) |